ANIKA THERAPEUTICS INC

ANIKNASDAQ

🏆 #2830 by market capEarnings Nov 3US Equity

$911.84▲ $64.47 (+7.07%)

Simulated price

1h—

24h▲ 7.1%

7d—

14d—

30d—

1y—

🏦Market Cap

$284M

Small Cap

📈Revenue Growth (YoY)

-2.5%

Declining

📊Gross Margin

62.2%

High

💵FCF Margin

7.4%

Moderate

⚖️P/S Ratio

2.3x

Cheap

Otter Score

Fair

No chart data available for ANIK.

Trading Snapshot

Day Range: $901.16 – $921.31
52-Week Range: $7.92 – $22.88
Volume: $3.28B
Avg Volume: $3.09B
Shares Outstanding: 13.4M
Next Earnings: Oct 9, 2026

Fundamentals Snapshot

Annual Revenue: $113M
Last Q Revenue: $33M
P/E Ratio: —
P/S Ratio: 2.3x
EPS (TTM): $-0.27
Dividend Yield: —

Why Investors Own ANIK

✓High-growth profile — revenue up +22.1% YoY with expanding US Equity exposure.
✓Healthy economics — 30% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$113M▲ +26.5% YoY

Gross Margin (TTM)

30.2%▼ −0.1% YoY

Operating Income (TTM)

$14M▲ +26.5% YoY

Free Cash Flow (TTM)

$11M▲ +26.5% YoY

About ANIKA THERAPEUTICS INC

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.

🦦